SCHEMBL19911519

SCHEMBL19911519

COc1ccc2c(c1)nnn2S(=O)(=O)c1cccnc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
SLC9A1 P19634 2/20 0.46
NFE2L2 Q16236 2/20 0.45
KEAP1 Q14145 1/20 0.44
POLB P06746 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GAA P10253 2/20 0.44
LMNA P02545 2/20 0.43
RAD51 Q06609 1/20 0.42
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
PIK3CD O00329 1/20 0.41
MET P08581 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HTR6 P50406 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19848252 0.91 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL1SLC9A1NFE2L2KEAP1
SCHEMBL19911507 0.86 SLC9A1 (0.62) SMN1; SMN2L3MBTL1SLC9A1POLBMEN1
SCHEMBL19848122 0.84 SLC9A1 (0.54) SMN1; SMN2L3MBTL1SLC9A1NFE2L2KEAP1
SCHEMBL19848250 0.81 SLC9A1 (0.49) L3MBTL1SLC9A1NFE2L2KEAP1POLB
SCHEMBL19911619 0.81 SLC9A1 (0.49) SMN1; SMN2SLC9A1NFE2L2POLBMEN1
SCHEMBL19911461 0.80 SLC9A1 (0.47) SMN1; SMN2SLC9A1POLBKMT2AGAA
SCHEMBL29479890 0.79 SLC9A1 (0.72) SMN1; SMN2L3MBTL1SLC9A1POLBMEN1
SCHEMBL4339723 0.79 SLC9A1 (0.72) SMN1; SMN2L3MBTL1SLC9A1POLBMEN1
SCHEMBL19848292 0.79 KMT2A (0.46) SMN1; SMN2SLC9A1KMT2ALMNATSHR
SCHEMBL19848526 0.79 SLC9A1 (0.46) SLC9A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-08-25 US disclosed
EP-3467930-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY ASAHI KASEI KABUSHIKI KAISHA (JP) 2019-04-10 EP disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery BPTF, BRD4, KCNN2 SMN1; SMN2 3476/4885L3MBTL1 2127/4885SLC9A1 341/4885
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 SMN1; SMN2 3476/4885L3MBTL1 2127/4885SLC9A1 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.